Literature DB >> 23412561

Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization.

Sandra Heesch1, Martin Neumann, Stefan Schwartz, Isabelle Bartram, Cornelia Schlee, Thomas Burmeister, Matthias Hänel, Arnold Ganser, Michael Heuser, Clemens-Martin Wendtner, Wolfgang E Berdel, Nicola Gökbuget, Dieter Hoelzer, Wolf-Karsten Hofmann, Eckhard Thiel, Claudia D Baldus.   

Abstract

Acute leukemias of ambiguous lineage represent a heterogeneous group of rare, poorly characterized leukemias with adverse outcome. No larger studies have yet performed a combined approach of molecular and clinical characterization of acute undifferentiated leukemia (AUL) and biphenotypic acute leukemia (BAL) in adults. Here we describe 16 adults with AUL and 26 with BAL and performed mutational as well as expression studies of genes with prognostic impact in acute leukemia (BAALC, ERG, MN1, WT1, and IGFBP7). AUL showed overexpression of these genes compared to T-lymphoblastic leukemia (T-ALL), B-precursor ALL, and to acute myeloid leukemia (AML). Genotype alterations were not detectable in AUL. BAL samples were characterized by frequent WT1 mutations (18 %) and BCR-ABL translocations (30 %). ALL-based treatment protocols induced complete remissions in 40 % and AML-like therapies in 22 % of AUL/BAL patients. The outcome in both groups was very poor; a long-term survival was only observed in patients undergoing allogeneic stem cell transplantation (SCT). Our findings indicate that AUL and BAL share important molecular and high-risk features of both myeloid and lymphoid leukemias. BAL patients exhibited genetic alterations, which can be targeted therapeutically. Importantly, ALL therapy might be more effective than AML protocols and AUL/BAL patients should be considered for allogeneic SCT.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23412561     DOI: 10.1007/s00277-013-1694-4

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  13 in total

1.  Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia.

Authors:  Reinhold Munker; Ruta Brazauskas; Hai Lin Wang; Marcos de Lima; Hanna J Khoury; Robert Peter Gale; Richard T Maziarz; Brenda M Sandmaier; Daniel Weisdorf; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2016-02-21       Impact factor: 5.742

2.  Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia.

Authors:  Bartlomiej M Getta; Mikhail Roshal; Junting Zheng; Jae H Park; Eytan M Stein; Ross Levine; Esperanza B Papadopoulos; Ann A Jakubowski; Nancy A Kernan; Peter Steinherz; Richard J O'Reilly; Miguel-Angel Perales; Sergio A Giralt; Martin S Tallman; Brian C Shaffer
Journal:  Biol Blood Marrow Transplant       Date:  2017-07-08       Impact factor: 5.742

3.  Molecular Complete Remission Following Ivosidenib in a Patient With an Acute Undifferentiated Leukemia.

Authors:  Sandipkumar H Patel; Sumithira Vasu; Ling Guo; Olivia Lemaster; John C Byrd; Alison Walker
Journal:  J Natl Compr Canc Netw       Date:  2020-01       Impact factor: 11.908

4.  Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations.

Authors:  Xiaoli Mi; Gabriel Griffin; Winston Lee; Sanjay Patel; Robert Ohgami; Chi Young Ok; Sa Wang; Julia T Geyer; Wenbin Xiao; Mikhail Roshal; Jacqueline S Garcia; Lewis B Silverman; Stephen E Sallan; Jon C Aster; Marian H Harris; Olga K Weinberg
Journal:  Am J Hematol       Date:  2018-09-26       Impact factor: 10.047

5.  Hypocellular Philadelphia chromosome-positive mixed-phenotype acute leukemia successfully treated with dasatinib: A case report.

Authors:  Shin Lee; Kei Fujita; Hiroto Wakayama; Yusuke Kito; Takeshi Hara; Hisashi Tsurumi
Journal:  Mol Clin Oncol       Date:  2021-12-14

6.  Rare Case of Mixed Phenotype Acute Leukemia Presenting as a Myeloid Sarcoma Without Leukemic Involvement.

Authors:  Jeffrey Means; David Feldman; Allison Shaw; Khoan Vu
Journal:  Perm J       Date:  2022-04-05

Review 7.  Mixed Phenotype Acute Leukemia: Current Approaches to Diagnosis and Treatment.

Authors:  Thomas B Alexander; Etan Orgel
Journal:  Curr Oncol Rep       Date:  2021-02-05       Impact factor: 5.075

8.  Mixed-phenotype acute leukemia: suboptimal treatment when the 2008/2016 WHO classification is used.

Authors:  Alan Pomerantz; Sergio Rodriguez-Rodriguez; Roberta Demichelis-Gomez; Georgina Barrera-Lumbreras; Olga Barrales-Benitez; Xavier Lopez-Karpovitch; Alvaro Aguayo-Gonzalez
Journal:  Blood Res       Date:  2016-12-23

9.  Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing.

Authors:  Andrés E Quesada; Zhihong Hu; Mark J Routbort; Keyur P Patel; Rajyalakshmi Luthra; Sanam Loghavi; Zhuang Zuo; C Cameron Yin; Rashmi Kanagal-Shamanna; Sa A Wang; Jeffrey L Jorgensen; L Jeffrey Medeiros; Chi Young Ok
Journal:  Oncotarget       Date:  2018-01-03

10.  B/T mixed phenotype acute leukemia with high hyperdiploidy and lineage switch to B-cell acute leukemia.

Authors:  Hanaa Skhoun; Mohammed Khattab; Zahra Takki Chebihi; Aziza Belkhayat; Nadia Dakka; Jamila El BaghdadI
Journal:  Leuk Res Rep       Date:  2022-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.